Pharsight

Patent	Proceeding Filing Date	Status	Respondent	Petitioner

US8440170	November, 2015	Terminated-Adverse Judgment	ALPEX PHARMA	Erich Spangenberg

Drug Patent Number	Company	Drug Patent Title	Drug Patent Expiry
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US6149938	CITIUS PHARMS	Process for the preparation of a granulate suitable to the preparation of rapidly disintegrable mouth-soluble tablets and compositions obtained thereby	Jul, 2018 (5 years ago)
US8440170	CITIUS PHARMS	Orally disintegrating tablets with speckled appearance	Mar, 2029 (4 years from now)

Suprenza is owned by Citius Pharms.

Suprenza contains Phentermine Hydrochloride.

Suprenza has a total of 2 drug patents out of which 1 drug patent has expired.

Expired drug patents of Suprenza are:

Suprenza was authorised for market use on 13 June, 2011.

Suprenza is available in tablet, orally disintegrating;oral dosage forms.

The generics of Suprenza are possible to be released after 14 March, 2029.

Market Authorisation Date: 13 June, 2011

Treatment: NA

Dosage: TABLET, ORALLY DISINTEGRATING;ORAL

Strength	Submission Date	ANDA(s) Filed	First applicant approval	Last patent expiry	180 day status
15 mg and 30 mg	19 Oct, 2012	1	28 Jun, 2017	23 Jul, 2018	Deferred
37.5 mg	22 Mar, 2013	1	28 Jun, 2017	23 Jul, 2018	Deferred

Strength	Dosage	Availability
15MG Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons	TABLET, ORALLY DISINTEGRATING;ORAL	Discontinued
37.5MG Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons	TABLET, ORALLY DISINTEGRATING;ORAL	Discontinued
30MG Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons	TABLET, ORALLY DISINTEGRATING;ORAL	Discontinued

Suprenza patents expiration